11
2021-10
Suzhou, October 11 , 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the clinical trial of ALK-1 antibody (GT90001C) and Nivolumab (Opdivo®) combination therapy for the treatment of systemic therapy naïve patients with advanced hepatocellular carcinoma (“HCC”) was approved by the National Medical Products Administration (the “NMPA”) of China on October 9, 2021.
04
2021-10
Suzhou, October 4 , 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that on October 1 its phase III clinical trial of proxalutamide for the treatment of hospitalized COVID-19 patients has enrolled and dosed its first patient in the United States. Proxalutamide is the only small-molecule oral drug which has entered the phase III MRCT clinical trial for treating hospitalized COVID-19 patients.
26
2021-09
Suzhou, September 26, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that on September 22 the Brazilian Health Regulatory Agency (ANVISA) granted an approval for the phase III clinical trial of proxalutamide to treat hospitalized COVID-19 patients. This is the third ANVISA-approved pivotal study sponsored by Kintor Pharma for the treatment of COVID-19 patients with proxalutamide.
08
2021-09
Suzhou, September 8, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of pyrilutamide ("KX-826", tincture) in China for the treatment of androgenetic alopecia (AGA) was met, which was statistically significant and clinically meaningful.
06
2021-09
Kintor Pharma Included in Hong Kong Stock Connect Program
Suzhou, September 6, 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company’s stock has been included in the Hong Kong Stock Connect program (the “Hong Kong Stock Connect”), effective September 6, 2021.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn